AstraZeneca said a combination of two of its new oncology drugs failed to shrink lung cancer tumors in a clinical trial, casting doubt on a central part of its ambitious growth plans. Shares fell 16%.
from WSJ.com: US Business http://ift.tt/2uB7DDz
via IFTTT
No comments:
Post a Comment